Tempus AI, despite recent stock volatility due to lock-up expiration and insider selling, shows strong long-term potential in healthcare technology. Its 'Intelligent Diagnostics' uses generative AI for personalized treatments, positioning it as a leader in precision medicine. The company is experiencing robust revenue growth but is still unprofitable, with recent acquisitions and investments aimed at strengthening its market position.